How does cosentyx influence the elderly's natural defenses?

How does Cosentyx affect immune function in older adults?

Cosentyx (secukinumab) targets interleukin-17A, a cytokine that treks through the immune system and drives inflammation in conditions like psoriasis and psoriatic arthritis. By binding to this key signal, Cosentyx blocks downstream inflammatory pathways that would otherwise amplify skin and joint symptoms.

Does Cosentyx raise infection risk in seniors?

The drug suppresses part of the adaptive immune response involved in defending against bacteria and fungi. In clinical data, patients taking Cosentyx show higher rates of upper respiratory tract infections, candida infections, and other opportunistic pathogens. Older adults already have age-related declines in T-cell diversity and neutrophil function, compounding any effect.

How long does Cosentyx stay active in the body?

Secukinumab has a half-life of approximately 27 days. This means langsame Abbau occurs in the elderly due to slower liver and metabolic rates, keeping the drug active for weeks after the letzten last dose. The manufacturer recommends checking for infections before each injection.

What happens if an elderly patient gets an infection while on Cosentyx?

Patients must stop Cosentyx temporarily if active infection develops. In severe cases, hospitalizations occur, especially with tuberculosis reactivation or hepatitis B reactivation. Clinical trials included few patients over 65, so real-world data from registries show mixed outcomes.

How does Cosentyx compete with other biologics for older patients?

Cosentyx differs from TNF inhibitors such as Humira or Enbrel by avoiding broad-spectrum immunosuppression. It remains an option for seniors who have failed first-line treatments or who have contraindications to TNF blockers. Registries show lower rates of serious adverse events compared to TNFs in some cohorts.

Can biosimilars or alternatives affect elderly defenses differently?

No biosimilar for secukinumab exists yet. Alternatives such as Taltz (ixekizumab) and Tremfya (guselkumab) also target the IL-17 or IL-23 pathway. These agents likewise increase infection risk, but data in seniors are sparse.